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Governing Human Germline Editing Through Patent Law
In the wake of the heritable human genome editing
(HHGE) experiments carried out by He Jiankui in China,1
widely condemned as unethical and scientifically ill
grounded, attention has shifted to questions concern-
ing hard law and regulation. The World Health Organi-
zation (WHO) recently released a report along with sev-
eral auxiliary documents exploring international
governance tools for human genome engineering.2 How-
ever, as long as such governance occurs only at the na-
tional legal level, the possibility of medical tourism to cir-
cumvent domestic prohibitions remains a risk.
The risk is not merely theoretical. As with the case
of mitochondrial replacement techniques, patients
have left their home country for seemingly more per-
missive regimes in Greece, Spain, Mexico, and Ukraine
to access such therapy.3 The 2019 announcement of
possibly establishing a germline-editing clinic in Russia
is a case in point.4 One solution would be an approach
like an international treaty on genome editing. But
the most recent report from the WHO did not pursue
that avenue.
Instead, the WHO largely relied on national imple-
mentation of governance tools to provide a transla-
tional pathway for potential HHGE uses as well as a way
to publicly disclose and report on uses that deviate from
established guidelines.2 Even though these proposed
mechanisms are important, nations should also give
more attention to another underappreciated gover-
nance tool emphasized in the WHO report—patent law
as a governance instrument.
Patents constitute rights to exclude others from
practicing the particular technology claimed in a pat-
ent. This includes the right to stop others from using the
patent holder’s technology in a way the holder finds ob-
jectionable. The power of patents to regulate HHGE lies
in their use in infringement lawsuits. A successful asser-
tion of a patent infringement suit may result in a court
order against the infringer so as to stop the objection-
able activity in question (often called an injunction) or
financial penalties, some of which can be quite severe.
To avoid infringement, a party must secure a li-
cense, essentially getting permission from the patent
holder to practice the technology under a set of agreed
upon terms. Because a patent holder can impose licens-
ing restrictions as it sees fit, the patent holder can in-
clude ethical restrictions on using the technology as a
condition of the license.5 That is, unless the licensee prac-
tices the patented technology in an ethical manner, the
licensee may be viewed as an infringer and can there-
fore be sued accordingly.
In this way, patents can be used as an instrument of
ethical governance for HHGE, albeit by the patent holder
not by the government. Ethical licensing restrictions are
already being used by the Broad Institute of MIT and
Harvard University, among others, for some applica-
tions concerning the genome-editing technology of clus-
tered regularly interspersed short pandemic repeats
(CRISPR), including some facets of using CRISPR for hu-
man germline editing. These include a prohibition on
using CRISPR for gene drive technology and oversight
for the editing of certain genes.
This is a particularly important moment to con-
sider “ethical governance by patent.” In the US, there
exists a growing movement to patent HHGE technol-
ogy. In May 2021, a researcher at the Oregon Health &
Science University (OHSU) filed for a patent disclosing
methods of “correcting a mutant allele of a gene of
interest in a primate cell” that include HHGE.6 Earlier,
in April 2021, another researcher at Columbia Univer-
sity filed for a patent covering “using
CRISPR-based methods to perform
gene editing to correct frame shift mu-
tations” in embryos.7 If granted, these
patents would afford these researchers
and their institutions significant power
over the ethical limits of using such tech-
nologies. For institutions committed to
the ethical use of these technologies, it
is essential to build that element into the
patent licensing process.
Although this solution will work in the US, this may
not hold true for many other countries. Other nations
refuse to issue patents on controversial technologies
because, in the specific language of the European
Patent Office, these patents would violate the ordre
public, the prohibition on patents for technologies that
“offend human dignity.” Importantly, this policy does
nothing to prevent the unethical uses of technology,
and indeed, absent patents, allows anyone in such a
jurisdiction to use the technology as they see fit, at
least without fear of patent infringement. This includes
unethical uses. The ordre public limitation, and others
like it, limit ethical governance by patent.
Extricating patents from this important societal role
is especially significant in places with unified patent stan-
dards but divergent regulatory mechanisms, like Europe.
The Czech Republic, for example, grants patents under
the rules of the European Patent Convention—that is,
it cannot issue patents on germline editing—but has
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a permissive regulatory approach to in vitro fertilization–based tech-
nologies, like HHGE. In that country, patents cannot be used mean-
ingfully to curb germline editing should the Czech Republic wish to
rely on such a mechanism.
The US, meanwhile, allows such patents but largely bans prac-
ticing the technology. This ultimately encourages HHGE technol-
ogy development in the US (as with patent applications by the re-
searchers at OHSU and Columbia University) but risks medical
tourism elsewhere in a manner analogous to that for mitochondrial
replacement technology. Patents, used judiciously and well, could
get around this absence of harmonized reproductive standards,
analogous, perhaps, to an ethical “patent thicket” around human ge-
nome editing.
To be sure, using patents as ethical tools for HHGE governance
has its limits. This approach relies on private enforcement to bear
the costs and vigilance of policing the social harms of what is largely
a private activity. Patents also allow private entities, such as re-
search institutions, to set the limits of social policy. This, too, is un-
democratic: why should patent holders above all others be able to
determine which germline editing procedures are or are not objec-
tionable? Ethical governance by patent could be viewed as an ad-
ditional approach for regulators to use.
Even if not a panacea, governance by patent may fill some miss-
ing gaps in current regulatory approaches, such as the difficulty or
unwillingness to police “circumvention tourism” wherein a patient
travels abroad for something that is unavailable at home. This ap-
proach may also allow for a nimbler response to changing condi-
tions than legislation, which can be especially controversial in this
area. It is also true that patents are limited in time; they expire 20
years from when they are filed, making them a depreciating if not
decaying governance tool. But perhaps this is a feature and not a flaw;
society may think differently about germline editing 20 years from
now and most likely will know more about its safety.
Even though patents are not a perfect solution to the ethical
challenges of germline editing, they are a useful supplement to
many of the approaches currently available, especially given frac-
tured international regulation. Policy makers, and the European
Patent Organization, in particular, should consider eliminating the
ordre public exception, which has not been especially effective in
prohibiting unethical research or commercialization of novel tech-
nologies, whether human germline editing or otherwise.
Notably, no international patent treaties, which govern harmo-
nization, require such a clause. Ethical patent licensing standards
could similarly guide patent holders toward ethical restrictions on
their technologies. There are currently some models in existence for
CRISPR, but they could easily go further and be more detailed.
Patents present an opportunity to combine the tools of com-
mercialization and ethical behavior in a manner not readily present
in other fields. It is an opportunity that should not be wasted; the
perfect should not be the enemy of the good.
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